Search

Displaying results 3721 - 3730 of 10000 in total
  1. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    After the first cord blood transplant in 1988 in a patient with Fanconi anemia [A32220], the use of umbilical cord blood transplantation was increased in clinical settings. … donor transplant setting has several advantages over related donor transplant and bone marrow transplantation; it allows shorter time to transplant and tolerance of 1–2 human leukocyte antigen mismatch due

  2. Drug

    Flotufolastat F-18

    go.drugbank.com/drugs/DB17851
    ApprovedInvestigational

    [A259846] In May 2023, the FDA approved the use of flotufolastat F-18 for PET of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive … therapy or suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

  3. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen

    go.drugbank.com/drugs/DB10284
    ApprovedInvestigational

    It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily

    Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML
  4. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    Etuvetidigene autotemcel is an autologous gene therapy which includes hematopoietic stem cells (HSCs) that have been genetically modified ex vivo. … [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878]

  5. Drug

    Gestrinone

    go.drugbank.com/drugs/DB11619
    Approved

    However, from 1982 this drug attracted increased interest due to significant therapeutic effects in the treatment endometriosis. … Gestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America.

  6. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  7. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

    Mixtures: Regulex D CapInternational brands: Scatron D
  8. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

  9. Drug

    Fluocinonide

    go.drugbank.com/drugs/DB01047
    ApprovedInvestigational

    A topical glucocorticoid used in the treatment of eczema.

    Products: Lidex-E
  10. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment … cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.